These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 24056893)

  • 21. Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors.
    Narita Y
    Jpn J Clin Oncol; 2013 Jun; 43(6):587-95. PubMed ID: 23585688
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial.
    Galanis E; Anderson SK; Lafky JM; Uhm JH; Giannini C; Kumar SK; Kimlinger TK; Northfelt DW; Flynn PJ; Jaeckle KA; Kaufmann TJ; Buckner JC
    Clin Cancer Res; 2013 Sep; 19(17):4816-23. PubMed ID: 23833308
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcome of discontinuing bevacizumab prior to malignant glioma progression.
    Sherman WJ; Raizer JJ; Grimm SA
    J Neurooncol; 2013 Jan; 111(1):87-9. PubMed ID: 23065093
    [No Abstract]   [Full Text] [Related]  

  • 24. Bevacizumab alone at 5 mg/kg in an every-3-week schedule for patients with recurrent glioblastomas: a single center experience.
    Kaloshi G; Brace G; Rroji A; Bushati T; Roci E; Hoxha M; Fejzo G; Petrela M
    Tumori; 2013; 99(5):601-3. PubMed ID: 24362864
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glioblastoma survival in the United States improved after Food and Drug Administration approval of bevacizumab: a population-based analysis.
    Johnson DR; Leeper HE; Uhm JH
    Cancer; 2013 Oct; 119(19):3489-95. PubMed ID: 23868553
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complete remission after bevacizumab plus temozolomide in a patient with recurrent glioblastoma multiforme.
    Kilickap S; Oztoprak I; Yucel B
    Acta Oncol; 2012 Apr; 51(4):544-6. PubMed ID: 22201408
    [No Abstract]   [Full Text] [Related]  

  • 27. Case report of interstitial nephritis induced by bevacizumab therapy for glioblastoma multiforme.
    Lomax AJ; Hill PA; Ashley DM
    J Oncol Pharm Pract; 2013 Dec; 19(4):365-8. PubMed ID: 23235917
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bevacizumab has differential and dose-dependent effects on glioma blood vessels and tumor cells.
    von Baumgarten L; Brucker D; Tirniceru A; Kienast Y; Grau S; Burgold S; Herms J; Winkler F
    Clin Cancer Res; 2011 Oct; 17(19):6192-205. PubMed ID: 21788357
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Impact of Bevacizumab in Patients with Relapsed Glioblastoma: Focus on a Real-Life Monocentric SurVey (SV1 Study).
    Rivoirard R; Chargari C; Guy JB; Nuti C; Peoc'h M; Forest F; Falk AT; Garin C; Adjabi A; Hoarau D; Fotso MJ; Langrand Escure J; Moriceau G; Fournel P; Boutet C; Magné N
    Chemotherapy; 2016; 61(5):269-74. PubMed ID: 27057742
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial.
    Dirven L; van den Bent MJ; Bottomley A; van der Meer N; van der Holt B; Vos MJ; Walenkamp AM; Beerepoot LV; Hanse MC; Reijneveld JC; Otten A; de Vos FY; Smits M; Bromberg JE; Taal W; Taphoorn MJ;
    Eur J Cancer; 2015 Jul; 51(10):1321-30. PubMed ID: 25899986
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bevacizumab therapy for glioblastoma: a passionate discussion.
    Desjardins A; Friedman HS
    CNS Oncol; 2014 Jan; 3(1):1-3. PubMed ID: 25054891
    [No Abstract]   [Full Text] [Related]  

  • 32. Role of arterial hypertension as a predictive marker for bevacizumab efficacy in recurrent glioblastoma - a prospective analysis.
    Wagner CC; Held U; Kofmehl R; Battegay E; Zimmerli L; Hofer S
    Acta Oncol; 2014 Apr; 53(4):572-5. PubMed ID: 24219539
    [No Abstract]   [Full Text] [Related]  

  • 33. Bevacizumab in glioblastoma--still much to learn.
    Fine HA
    N Engl J Med; 2014 Feb; 370(8):764-5. PubMed ID: 24552324
    [No Abstract]   [Full Text] [Related]  

  • 34. Rare serious complications of erlotinib therapy.
    Kapoor S
    Acta Neurochir (Wien); 2013 Apr; 155(4):743. PubMed ID: 23361636
    [No Abstract]   [Full Text] [Related]  

  • 35. Avastin: more questions than answers. .
    Desjardins A; Sampson JH
    J Neurosurg; 2012 Feb; 116(2):336-40; discussion 340. PubMed ID: 22035270
    [No Abstract]   [Full Text] [Related]  

  • 36. ASCO 2013: bevacizumab and glioblastoma--a marriage dissolution?
    Addeo R; Perri F; Parlato C; Della Vittoria G
    Curr Med Res Opin; 2014 Sep; 30(9):1871-3. PubMed ID: 24803042
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Questions regarding the optimal use of bevacizumab in glioblastoma: a moving target.
    Stupp R; Weller M
    Neuro Oncol; 2014 Jun; 16(6):765-7. PubMed ID: 24826844
    [No Abstract]   [Full Text] [Related]  

  • 38. Single-agent bevacizumab is an effective treatment in recurrent glioblastoma.
    Hacibekiroglu I; Kodaz H; Erdogan B; Turkmen E; Ozcelik M; Esenkaya A; Saygi HM; Uzunoglu S; Cicin I
    Med Oncol; 2015 Feb; 32(2):460. PubMed ID: 25572814
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Response to: "rare serious complications of erlotinib therapy".
    D'Alessandris QG; Pallini R
    Acta Neurochir (Wien); 2013 Apr; 155(4):745. PubMed ID: 23275073
    [No Abstract]   [Full Text] [Related]  

  • 40. Early perfusion changes in patients with recurrent high-grade brain tumor treated with Bevacizumab: preliminary results by a quantitative evaluation.
    Vidiri A; Pace A; Fabi A; Maschio M; Latagliata GM; Anelli V; Piludu F; Carapella CM; Giovinazzo G; Marzi S
    J Exp Clin Cancer Res; 2012 Apr; 31(1):33. PubMed ID: 22494770
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.